Medicare Will Be Leading Payer For Hepatitis C By 2017 – Milliman Report
This article was originally published in The Pink Sheet Daily
Commissioned by Janssen Therapeutics, the report focuses on how a number of changes in the U.S. health care environment will increase access to diagnosis and treatment for patients with hepatitis C and also change who pays for care.
You may also be interested in...
While Olysio will be priced higher than Incivek for the course of therapy, J&J has a broader strategy for use of the second-generation protease inhibitor. Market analysts are skeptical about the drug’s prospects even though it has some clear edges over the first-generation protease inhibitors for hepatitis C.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’